NRXP - NASDAQ

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc.

NRXP·NASDAQ

$4.13

+2.1%
HealthcareBiotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$71.48M
EPS-1.3400
P/E Ratio-3.09
Earnings Date08/17/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. Earnings Call Transcripts

NRXP · NASDAQ

Related Guides

Blog Categories

Continue your NRXP research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.